This article discusses recent findings from investigations that utilize TriLink products while investigating mRNA therapeutic development for neurological conditions such as stroke, spinal cord injury, spinal disc degenerative disease, Niemann-Pick disease and peripheral neuropathy.

An antibacterial mRNA-LNP vaccine protects against the bubonic plague

Researchers at the Tel Aviv University used TriLink manufactured mRNA in an optimized vaccine for bubonic plague, which has been shown to protect mice against a lethal Y. pestis challenge.

A new Nature Biotechnology publication describes how TriLink’s N6-Methyladenosine-5'-Triphosphate enabled the validation eTAM-seq. This new technique provides an accurate way to identify and quantify sites of m6A on transcriptome-wide or single-site scales.

The TIDES USA conference (May 7 - 10) scientific agenda includes presentations from 150+ top scientists.  Topics include the latest science and industry updates in oligonucleotide, peptide, and mRNA-based therapeutics.

Enter our giveaways, help build a custom DNA helix out of Lego bricks, and contribute to our Innovation Wall – it's all happening at booth #5022

Featured Presentation

Date: May 7, 2023
Time: 12:30 PM ET
Title: Next-generation mRNA design – increasing mRNA potency with a new cap analog.
Speaker: Kate Broderick, PhD, Chief Innovation Officer, Maravai Life Sciences

A discussion on the development, manufacturing, and analysis of high-quality DNA & RNA utilizing both cell-based and cell-free processes. This includes the raw materials necessary for in vitro replication and/or transcription with a focus on the acquisition of quality nucleotides and recombinant enzymes as well as the lipids and other components required as part of the nanoparticle delivery system.

Featured Presentation

Date: May 9, 2023
Time: 10:30 AM ET
Title: Analytical framework consideration to support successful mRNA programs
Speaker: Khaled Yamout, Senior Director Analytical Services & Quality Control, TriLink BioTechnologies

Pharmaceutical Technology is hosting a live roundtable discussion.

There is a robust and promising therapeutic pipeline of mRNA-based cell therapies. This roundtable panel will discuss critical barriers in the drug substance development process for mRNA-based cell therapies. The discussion will include process development lessons learned, insights from analytical development programs, and how manufacturing innovations can help you navigate and overcome these key barriers.

Date: May 23, 2023
Time: 11:00 AM ET / 8:00 AM PT
Title: Overcoming critical barriers when developing mRNA-based cell therapies
Speakers: Khaled Yamout, Senior Director Analytical Services & Quality Control, TriLink BioTechnologies
Evan Meyers, Associate Director, Process Development & Custom Development, TriLink BioTechnologies
Jordana Henderson, Associate Director, mRNA Research & Development, TriLink BioTechnologies